Miltefosine to Treat Mucocutaneous Leishmaniasis

Completed · Phase 2

Conditions studied: Mucosal Leishmaniasis, Cutaneous Leishmaniasis

In brief

The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States. If entrance criteria were met, subjects with mucosal or cutaneous leishmaniasis received miltefosine at a targeted dose of 2.5 mg/kg/day for 28 days. During treatment at weeks 1, 2, and 4, the patient returned to the treatment facility to be assessed for adverse events. Blood for transaminase and creatinine values were drawn at the midpoint and at the end of therapy. Patients returned to the treatment facility to be examined clinically at 6 weeks (ie, 2 weeks after the end of therapy), 3 months (2 months after therapy), and 7 months (6 months after treatment) for mucosal leishmaniasis and cutaneous leishmaniasis patients, and also at 13 months (12 months after treatment) for mucosal leishmaniasis patients.

Key facts

Study ID

NCT01050907

Run by

Knight Therapeutics (USA) Inc

People needed

4

Starts

2010-05-01

Expected to finish

2015-03-01

Last updated by the study team

2020-09-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is the subject a male or female at least 18 years of age?
• Does the subject weigh at least 30 kg?
• Does the subject have a diagnosis of mucosal leishmaniasis or cutaneous leishmaniasis in at least one lesion by at least one of the following methods: 1) positive culture for promastigotes of lesion material, 2) microscopic identification of amastigotes in stained lesion tissue, 3) Polymerase chain reaction of lesion material?
• In the opinion of the investigator, is the subject capable of understanding and complying with the protocol?
• If female and of child-bearing potential, did the subject have a negative pregnancy test during screening and agree to use an acceptable method of birth control during the treatment phase and for 6 months after treatment is completed?
• Has the patient signed informed consent?

You may not qualify if…

• Is the subject a female who is breast-feeding?
• Does the subject have a clinically significant medical disorder?
• Thrombocyte count <100 x 10e9/L
• Leukocyte count <3 x 10e9/L
• Haemoglobin <10 g/100 mL
• Aspartate transaminiase (ASAT), alanine transaminase (ALAT) >2 times upper limit of normal range
• Bilirubin >1.5 times upper limit of normal range
• Serum creatinine >1.5 times upper limit of normal range
• Major surgery within last 2 weeks
• Any non-compensated or uncontrolled condition
• In the last 4 weeks up to the present, has the subject received other treatment for leishmaniasis, including any medication with pentavalent antimony; amphotericin B, paromomycin, or imidazoles?

Where it is running

• For this treatment IND, each Physician entered patients at his/her own facility. Below data is for protocol central contact: — Bethesda, Maryland, United States
• NIH — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.